Search results

Skip to results

Type

Status

Last updated

Showing 1 to 4 of 4 results for ta245

  1. Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults (TA245)

    Evidence-based recommendations on apixaban (Eliquis) for preventing venous thromboembolism after total hip or knee replacement in adults.

    Technology appraisal guidance
    Published
    25 January 2012
    View recommendations

    Sections for TA245

  2. Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism (NG89)

    This guideline covers assessing and reducing the risk of venous thromboembolism (VTE or blood clots, including deep vein thrombosis and pulmonary embolism) in people aged 16 and over in hospital. It aims to help healthcare professionals identify people most at risk and describes interventions that can be used to reduce the risk of VTE.

    NICE guideline
    Last updated
    13 August 2019
    View recommendations

    Sections for NG89

  3. More trials of apixaban compared with other low molecular weight heparin (LMWHs) in total hip and knee replacement would decrease the uncertainty of the clinical and cost effectiveness of these treatments. Trials directly comparing apixaban with rivaroxaban, dabigatran etexilate and fondaparinux would strengthen the evidence base for these comparisons.

    Recommendation ID TA245/1 Question More trials of apixaban compared with other low molecular weight heparin (LMWHs) in total hip and knee

    Research recommendation
    Published
    9 June 2015

  4. Research recommendations

    TA245/1 | More trials of apixaban compared with other low molecular weight heparin